Ipsen Global - A Biopharmaceutical Company | Innovation for Patient Care

WHO WE ARE

As a mid-sized global biopharmaceutical company, Ipsen improves patients’ lives through research, innovation and the development of transformative medicines in Oncology, Rare Disease and Neuroscience.

WHAT WE DO

WHAT WE DO

Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.

Author Image

Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.

David Loew

CEO

 

PATIENTS

Putting patients at the heart of our work

Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire.

RESPONSIBILITY

RESPONSIBILITY

Shaping a more sustainable future

Ipsen is dedicated to safeguarding and preserving our planet. The Generation Ipsen ESG responsibility strategy lays out ambitious goals for the company in each of four pillars: Environment, Patients, People and Governance.

Careers at Ipsen

Ipsen offers a multitude of exciting opportunities for talented and motivated people in careers ranging from medial and clinical research to sales, marketing, finance, IT, HR and legal services. We are committed to providing our employees with a workplace that is welcoming, challenging and inclusive.

Discover trending stories

22 July 2024 0 mins read

Financial results for the first half of 2024

The financial results for the first half of the year will be published on July 25, 2024 at 7H00 and a conference call will take place at 13H00 CET.

15 July 2024 1 mins read

Ipsen shines at ESG Life Sciences Summit Europe 2024 

The ESG Life Sciences Summit Europe, held in June brought together industry leaders to discuss how the life sciences sector can drive meaningful change through ESG initiatives. 

26 June 2024 3 mins read

Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen 

When Eric Gratton joined Ipsen from a large financial services firm, he was surprised to find there wasn’t an employee resource group (ERG) dedicated to the LGBTQIA+ community. “Being the over-achiever I am, I thought I should start one: a little passion project for the community and its allies.”

05 June 2024 2 mins read

The importance of personalized care to empower patients with PBC 

At the European Association for the Study of the Liver (EASL) congress, leading liver experts discuss the importance of proactive, personalized care and shared decision-making during consultations. A personalized care approach begins by listening to the patient’s feelings and needs, which can result

31 May 2024 1 mins read

Our 2023 Integrated Annual Report is live!

In 2023, we entered the next phase of our journey of growth and innovation, reinforcing our position as a leading mid-sized biopharmaceutical company. With a sharp focus on our three therapy areas of Oncology, Rare Diseases, and Neuroscience, we achieved total sales of €3,128 m.

29 May 2024 1 mins read

Together, we can improve the lives of people living with kidney cancer

Together for Kidney Cancer is a global disease awareness initiative funded by Ipsen aiming to raise awareness of the reality of people’s experiences living with kidney cancer and the importance of shared decision making to inform better care outcomes.

22 May 2024 3 mins read

Ipsen’s Commitment to Biodiversity  

Biodiversity encompasses the rich array of species and ecosystems vital for our planet’s health. Yet, human activities have endangered this diversity, jeopardizing not only various species but also our daily lives. Biodiversity is crucial for human health, providing essential services such as pollin

20 May 2024 4 mins read

Exploring life and parenthood with Primary Biliary Cholangitis 

Sandra Silvestri, Executive Vice President & Chief Medical Officer at Ipsen, reflects on the challenges women living with primary biliary cholangitis (PBC) face and why we have big dreams of a better future for PBC.

20 May 2024 4 mins read

Improving Diversity in Research and Development to Drive Health Equity

To mark World Clinical Trials Day, we sat down with Christelle Huguet, Executive Vice President, Head of R&D at Ipsen to explore the importance of diversity from all sides of the research and development process, as we accelerate innovation.  

14 May 2024 2 mins read

Progressive Familial Intrahepatic Cholestasis (PFIC): Liver experts discuss early diagnosis and management 

Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare liver disease that can pose significant challenges, particularly in young children1, but the good news is that there are growing opportunities to manage the disease, slow its progression and improve outcomes.